Related to Collaboration Gives Boehringer Ingelheim Rights to Zealand’s Type 2 Diabetes Candidate

• Court Vacates Temporary Restraining Order Against Lilly in Case Filed by Amylin
  
• Scientists Trigger White Fat to Become Brown Fat-Like to Treat Obesty and Type 2 Diabetes
  
• BI Licenses ProBioGen’s GlymaxX Platform for Fucose-Free Antibody Production
  
• BI and Nuevolution Leverage Chemetics Platform in Drug Discovery Collaboration
  
• Gilead Negotiates Worldwide License to BI’s Early Clinical Stage HIV Program
  
• Aveo Signs BI on as Production Partner for Clinical-Stage mAb
  
• Abbott Pays Action $110M for Global Rights to Phase II-Stage Acute Kidney Injury Drug
  
• Boehringer Ingelheim, Polyphor Partner on Macrocyclic Drug R&D
  
• Rhythm Scores $25M to Advance Peptide Treatments for Metabolic Disorders
  
• Zealand Pharma, Protagonist to Develop Disulfide-Rich Peptide Therapeutics
  
• ChemAxon Boosts Boehringer Ingelheim toward Next-Gen Cheminformatics
  
• OBT Joins Boehringer Ingelheim in Cancer Drug Collaboration
  
• Boehringer Ingelheim Enters Deal with DeveloGen with an Initial Fee of $9.5M
  
• Zealand Pharma and Sanofi-Aventis Expand Type 2 Diabetes-Focused Partnership
  
• Zealand and Sanofi-Aventis Achieve First Phase III Success for Lixisenatide Monotherapy
  
• Zealand Pharma and Sanofi-Aventis’ Antidiabetic Sees Phase III Success
  
• FDA Approves Type 2 Diabetes Drug from Boehringer Ingelheim and Lilly
  
• Amylin Takes Lilly to Court over Diabetes Drug Development Deal with Boehringer Ingelheim
  
• Promising Data for Type 1 and 2 Diabetes Candidates Presented at ADA Meeting
  
• BI and Lilly’s Linagliptin Now Approved to Treat Type 2 Diabetes in Europe